Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48
Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $50 to $48.
Stocks · News reference
FDA Classifies Boston Scientific's Recall Of Imager II Angiographic Catheters As Class I Due To Potential Catheter Tip Degradation And Detachment Risk
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/angiographic-catheter-recall-boston-scientific-removes-imager-ii-angiographic-catheters
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig
ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic decision-making for manufacturers, investors, and healthcare stakeholders.
8-K filing — BOSTON SCIENTIFIC CORP (BSX)
Filed: 2026-09-23 AccNo: 0000885725-26-000061 Size: 180 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers